Singapur - Englisch - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - hematology - it is intended for the quantitative determination of cross-linked fibrin degradation products (d-dimers)in human citrated plasma. intended for use on sekisui coagulation analyzers by trained laboratory personnel in clinical laboratories. for invitro diagnostic use.

Singapur - Englisch - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clinical chemistry - the d-dimer assay is used for the quantitative determination of d-dimer in human citrated plasma on the alinity c system. the d-dimer assay is to be used as an aid for diagnosing thrombosis and monitoring thrombolytic therapy. elevated levels of d-dimer are found in clinical conditions such as deep vein thrombosis (dvt), pulmonary embolism (pe), and disseminated intravascular coagulation (dic). d-dimer levels also rise during the normal pregnancy, but very high levels are associated with complications.

Singapur - Englisch - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - clinical chemistry - liquichek d-dimer control is intended for use as an assayed quality control to monitor the precision of laboratory testing procedures for d-dimer.

Singapur - Englisch - HSA (Health Sciences Authority)

radiometer s.e.a. pte. ltd. - immunology - the d-dimer test is an in vitro diagnostic assay for the quantitative determination of d-dimer in edta, lithium-heparin or citrate whole-blood specimens on the aqt90 flex analyzer in point-of-care and laboratory settings. it is indicated as an aid in the diagnosis of venous thromboembolism (deep vein thrombosis and pulmonary embolism).

Singapur - Englisch - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - clinical chemistry - in vitro test for the quantitative immunological determination of fibrin degradation products (d-dimer and x-oligomers) in human plasma on roche/hitachi cobas c systems.

Singapur - Englisch - HSA (Health Sciences Authority)

biomed diagnostics pte ltd - immunology - hemosil d-dimer hs is an automated latex enhanced immunoassay for the quantitative determination of d-dimer in human citrated plasma on the acl top® family for use, in conjunction with a clinical pretest probability (ptp) assessment model to exclude venous thromboembolism (vte) in outpatients suspected of deep venous thrombosis (dvt) and pulmonary embolism (pe).

Singapur - Englisch - HSA (Health Sciences Authority)

biomed diagnostics pte ltd - immunology - hemosil d-dimer hs 500 is an automated latex enhanced immunoassay for the quantitative determination of d-dimer in human citrated plasma on the acl top® family systems for use, in conjunction with a clinical pretest probability (ptp) assessment model to exclude venous thromboembolism (vte) in outpatients suspected of deep venous thrombosis (dvt) and pulmonary embolism (pe).

Singapur - Englisch - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - hematology - roche diagnostics cobas integra tina-quant d-dimer gen.2 is an in vitro test for the quantitative immunological determination of fibrin degradation products (d-dimer and x-oligomers) in human plasma on cobas integra systems.

Singapur - Englisch - HSA (Health Sciences Authority)

beckman coulter singapore pte. ltd. - clinical chemistry - immuno-turbidimetric test for the quantitative determination of d-dimer in human plasma on beckman coulter au analysers. for in vitro diagnostic use only

Singapur - Englisch - HSA (Health Sciences Authority)

biomerieux singapore pte. ltd. - immunology - vidas® d-dimer exclusion ii™ is an automated quantitative test for use on the instruments of the vidas® family for the immunoenzymatic determination of fibrin degradation products (fbdp) in human plasma (sodium citrate) using the elfa technique (enzyme linked fluorescent assay). vidas® d-dimer exclusion ii™ is indicated for use in conjunction with a clinical pretest probability assessment model to exclude deep vein thrombosis (dvt) and pulmonary embolism (pe) disease in outpatients suspected of dvt or pe. vidas® d-dimer exclusion ii™ is indicated for use in the herdoo2 clinical decision rule (cdr) to assess the risk of recurrence of venous thromboembolism (vte) in women with a first unprovoked vte. risk stratification by this cdr is an aid to guide the duration of oral anticoagulant therapy.